ArticleIJU case reports2026
Multiple Cranial Neuropathies After Lenvatinib-Pembrolizumab Therapy for Metastatic Renal Cell Carcinoma: A Case Report.
Article in IJU case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multiple Cranial Neuropathies After Lenvatinib-Pembrolizumab Therapy for Metastatic Renal Cell Carcinoma: A Case Report.IJU case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Multiple cranial neuropathy is a rare manifestation of immune-related adverse events. To date, no cases have been reported during immune checkpoint blockade for metastatic renal cell carcinoma. This report describes a case of multiple cranial neuropathy that developed during lenvatinib and pembrolizumab combination therapy. Case Presentation: A 66-year-old man with metastatic clear cell renal cell carcinoma involving the maxilla received lenvatinib and pembrolizumab. After two months, he developed a rash and facial nerve palsy that resolved with corticosteroids. Pembrolizumab rechallenge later caused diplopia due to multiple cranial neuropathies, which improved after steroid pulse therapy. Two years after treatment initiation, disease control and pembrolizumab maintenance have continued without neurological recurrence. Conclusions: We report a rare case of multiple cranial nerve palsies that developed during lenvatinib-pembrolizumab therapy. Such neuropathies typically occur early, respond to corticosteroids, and require careful monitoring, as retreatment may lead to recurrence or new adverse events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.